New criteria for response to therapy in high grade MDS, focuses on pt centered outcomes.
Neoadjuvant immunotherapy is gaining momentum in breast (triple negative) and lung cancer, now showing promise in MSI high tumors.
Although immunotherapy did not beat chemotherapy but was non inferior and with more favorable safety.
I welcome additional comments from our Radiology Oncologists, but it seems patients may not need axillary surgery, this eliminated adverse events such as lymphedema.
In this study, Cetuximab beat Bevacizumab in left sided KRAS wild type colon cancer.
A way to avoid axillary dissection, with more neoadjuvant therapy treatments, this may help avoid unnecessary axillary dissection.Probably needs more validation with larger studies but is a good start.Also, the first related to radiological findings, so welcome input from our FCS Radiologists.
Confirms what we already know. No real surprises.
Three trial updates confirm what we already know and practice.
Confirms what we already know. No real surprises.
Confirms what we already know. No real surprises.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
